RS20050226A - Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia - Google Patents

Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia

Info

Publication number
RS20050226A
RS20050226A YUP-2005/0226A YUP20050226A RS20050226A RS 20050226 A RS20050226 A RS 20050226A YU P20050226 A YUP20050226 A YU P20050226A RS 20050226 A RS20050226 A RS 20050226A
Authority
RS
Serbia
Prior art keywords
bulimia
epa
anorexia nervosa
eicosapentaenoic acid
treating anorexia
Prior art date
Application number
YUP-2005/0226A
Other languages
English (en)
Inventor
David Frederick Horrobin
Agnes Ayton
Original Assignee
Laxdale Limited,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS20050226(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laxdale Limited, filed Critical Laxdale Limited,
Publication of RS20050226A publication Critical patent/RS20050226A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Elkosapentaenoične kiseline (EPA) je upotrebljena u tretmanu anoreksije nervoze, bulimije i srodnih kliničkih poremećaja.
YUP-2005/0226A 2002-09-16 2003-09-16 Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia RS20050226A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0221480.7A GB0221480D0 (en) 2002-09-16 2002-09-16 Treatment of anorexia nervosa (AN) and bulimia
PCT/GB2003/003985 WO2004024136A1 (en) 2002-09-16 2003-09-16 Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia

Publications (1)

Publication Number Publication Date
RS20050226A true RS20050226A (en) 2007-09-21

Family

ID=9944164

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0226A RS20050226A (en) 2002-09-16 2003-09-16 Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia

Country Status (20)

Country Link
US (1) US20060135608A1 (sr)
EP (1) EP1556028A1 (sr)
JP (1) JP2006503031A (sr)
KR (1) KR20050042823A (sr)
CN (1) CN1694694A (sr)
AU (1) AU2003269138A1 (sr)
BR (1) BR0317857A (sr)
CA (1) CA2499142A1 (sr)
GB (1) GB0221480D0 (sr)
HR (1) HRP20050245A2 (sr)
IS (1) IS7744A (sr)
MX (1) MXPA05002943A (sr)
NO (1) NO20051847L (sr)
NZ (1) NZ538793A (sr)
PL (1) PL375726A1 (sr)
RS (1) RS20050226A (sr)
RU (1) RU2330653C2 (sr)
TW (1) TW200410682A (sr)
WO (1) WO2004024136A1 (sr)
ZA (1) ZA200502161B (sr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US20070082949A1 (en) * 2003-11-14 2007-04-12 Hiroaki Ootani Agent for preventing and treating language disorders
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
KR101881982B1 (ko) 2006-12-28 2018-07-25 산토리 홀딩스 가부시키가이샤 신경 재생제
WO2008098375A1 (en) 2007-02-15 2008-08-21 Centre De Recherche Sur Les Biotechnologies Marines Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
US8816110B2 (en) 2007-02-15 2014-08-26 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
AU2008229604B2 (en) 2007-03-20 2013-05-30 Scf Pharma Inc. Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
ES2661217T3 (es) * 2009-06-15 2018-03-28 Amarin Pharmaceuticals Ireland Limited Composiciones y métodos para reducir los triglicéridos sin aumentar los niveles de LDL-C en un sujeto en terapia simultánea con estatinas
EP2673371A1 (en) * 2011-02-11 2013-12-18 E.I. Du Pont De Nemours And Company An eicosapentaenoic acid concentrate
US9447020B2 (en) 2013-10-31 2016-09-20 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
RU2545988C1 (ru) * 2013-11-12 2015-04-10 Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы Способ лечения хронического запора и функциональной анорексии
AU2019217673A1 (en) 2018-02-07 2020-09-24 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
US20210130897A1 (en) * 2018-04-16 2021-05-06 Quadrant Biosciences Inc. Salivary microrna levels in anorexia nervosa provide a liquid biopsy of metabolic and neuropsychiatric status
WO2019210424A1 (en) 2018-05-03 2019-11-07 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
CN109276262B (zh) * 2018-07-30 2021-01-26 中国科学院心理研究所 一种用于筛选高危进食障碍的检测系统
EP4125836A1 (en) * 2020-03-27 2023-02-08 Homeostasis Therapeutics, Limited Method of treatment for anorexia nervosa, bulimia and related clinical syndromes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes

Also Published As

Publication number Publication date
BR0317857A (pt) 2005-12-06
RU2330653C2 (ru) 2008-08-10
IS7744A (is) 2005-03-15
NZ538793A (en) 2007-05-31
WO2004024136A1 (en) 2004-03-25
MXPA05002943A (es) 2005-06-03
NO20051847L (no) 2005-04-15
CA2499142A1 (en) 2004-03-25
JP2006503031A (ja) 2006-01-26
HRP20050245A2 (en) 2005-10-31
PL375726A1 (en) 2005-12-12
CN1694694A (zh) 2005-11-09
GB0221480D0 (en) 2002-10-23
ZA200502161B (en) 2005-09-15
AU2003269138A1 (en) 2004-04-30
KR20050042823A (ko) 2005-05-10
US20060135608A1 (en) 2006-06-22
RU2005107416A (ru) 2006-01-20
TW200410682A (en) 2004-07-01
EP1556028A1 (en) 2005-07-27

Similar Documents

Publication Publication Date Title
NO20051847L (no) Eikosapentaensyre (EPA) for behandling av anoreksia nevrosa (AN) og bulimi.
HK1076541A1 (en) Electro-osmotic pumps and micro-channels
MY180762A (en) Combination therapy comprising glucose reabsorption inhibitors and ppar modulators.
EP1487877A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS
ZA200309808B (en) Compositions and methods for the diagnosis and treatment of tumor
ATE539701T1 (de) Zusammengesetzte schlinge zur behandlung von inkontinenz
RS20060320A (en) Substituted indazole-o-glucosides
DE122008000046I1 (de) Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und -tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
AU2002341920A1 (en) Chemical compounds
UA86042C2 (en) Substituted indazole-o-glucosides
AU2002358390A1 (en) Novel compounds
EP1670450B8 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
MXPA04003796A (es) Tioacetamidas sustituidas.
EP1284239A3 (de) Gerät zur elektrophysikalischen Wasserbehandlung
GB0003025D0 (en) Novel compounds
WO2004062443A3 (en) Power circuitry for beverage apparatus
GB2399019B (en) The structure containing the conductive medium for the source of the external high-power focusing ultrasonic treatment
PL363679A1 (en) Novel use of 2-phenyl-substituted imidazotriazinones
WO2004024064A8 (en) Compositions and methods for the diagnosis and treatment of tumor
HUP0103743A2 (hu) Dielektromosan gátolt, vezérelhető teljesítményű kisülőlámpa, valamint eljárás ennek üzemeltetésére
TW200510447A (en) Novel fusidic acid derivatives
GB0102408D0 (en) Chemical compounds
MXPA04007007A (es) Uso de inhibidores del intercambiador cloruro/bicarbonato dependiente del sodio para el tratamiento de enfermedades tromboticas e inflamatorias.
TJ387B (en) The present invention relates to medicine and can be used for treatment of inflammatory process of aleather.